Pharma Co. Misled Investors About Hepatitis Drug, Suit Says

Law360, Los Angeles (October 09, 2013, 6:32 PM ET) -- Biopharmaceutical company Achillion Pharmaceuticals Inc. was hit Wednesday with a proposed class action accusing the company of failing to disclose that its hepatitis drug sovaprevir doesn't interact well with certain other antiviral medications, which ultimately led to a drop in its stock price. 

Joseph Sniezak filed the lawsuit in Connecticut federal court, alleging New Haven, Ct.-based Achillion and some of its executives misrepresented to investors and in financial filings the results of its clinical trials for sovaprevir, maintaining the drug was safe and effective when tests...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Sniezak v. Achillion Pharmaceuticals, Inc. et al


Case Number

3:13-cv-01479

Court

Connecticut

Nature of Suit

Securities/Commodities

Judge

Alvin W. Thompson

Date Filed

October 8, 2013

Companies

Government Agencies